Jasper Therapeutics, Inc.
JSPR
$0.46
$0.00-0.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.49% | -27.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.60% | -35.89% | |||
| Operating Income | 11.60% | 35.89% | |||
| Income Before Tax | 51.43% | 29.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.43% | 29.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.43% | 29.89% | |||
| EBIT | 11.60% | 35.89% | |||
| EBITDA | 12.11% | 36.12% | |||
| EPS Basic | 71.81% | 35.38% | |||
| Normalized Basic EPS | 70.49% | 41.61% | |||
| EPS Diluted | 71.81% | 35.38% | |||
| Normalized Diluted EPS | 70.49% | 41.61% | |||
| Average Basic Shares Outstanding | 72.30% | 8.49% | |||
| Average Diluted Shares Outstanding | 72.30% | 8.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||